{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:38:35Z","timestamp":1787495915862,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,6,2]],"date-time":"2015-06-02T00:00:00Z","timestamp":1433203200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA127435, R01 CA179483 and P01 CA155258"],"award-info":[{"award-number":["R01 CA127435, R01 CA179483 and P01 CA155258"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chambers Family Advanced Myeloma Research Fund"},{"name":"Cobb Family Myeloma Research Fund"},{"name":"de Gunzburg Myeloma Research Fund"},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Shawna Ashlee Corman Investigatorship in Multiple Myeloma Research"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Proteasome inhibitors (\n                    <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                    ) and immunomodulatory agents (\n                    <jats:styled-content style=\"fixed-case\">IMID<\/jats:styled-content>\n                    s) have improved the overall survival (OS) of patients with multiple myeloma (\n                    <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\n                    ), but concerns have been raised about increased incidence of extramedullary disease (\n                    <jats:styled-content style=\"fixed-case\">EMD<\/jats:styled-content>\n                    ) after the combined use of\n                    <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                    s and\n                    <jats:styled-content style=\"fixed-case\">IMID<\/jats:styled-content>\n                    s for upfront therapy. We evaluated whether the addition of lenalidomide to bortezomib\u2010based front\u2010line regimens precipitated earlier development of\n                    <jats:styled-content style=\"fixed-case\">EMD<\/jats:styled-content>\n                    . We reviewed the charts of 117\n                    <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\n                    patients (median follow\u2010up from diagnosis 6\u00b71\u00a0years; range 0\u00b71\u201310\u00b72\u00a0years) enrolled in eight clinical trials of first\u2010line treatment with bortezomib\u2010based regimens, with or without lenalidomide. We assessed development of\n                    <jats:styled-content style=\"fixed-case\">EMD<\/jats:styled-content>\n                    as extraosseous (distant from bone) or osseous (originating from bone) plasmacytomas. The primary endpoint was time from diagnosis until development of\n                    <jats:styled-content style=\"fixed-case\">EMD<\/jats:styled-content>\n                    , based on imaging, biopsy and\/or physical examination. Any form of\n                    <jats:styled-content style=\"fixed-case\">EMD<\/jats:styled-content>\n                    at progression was observed in 40 (34\u00b72%) patients, including 21 (18%) osseous, 8 (7%) extraosseous and 11 (9%) both osseous and extraosseous. Median OS was 0\u00b79\u00a0years (range 0\u00b71\u20134\u00b78\u00a0years) after extraosseous\n                    <jats:styled-content style=\"fixed-case\">EMD<\/jats:styled-content>\n                    development. Sensitivity analyses with follow\u2010up times truncated at 5\u00a0years detected no statistically significant difference in rates of any\n                    <jats:styled-content style=\"fixed-case\">EMD<\/jats:styled-content>\n                    form between the two groups (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&gt;\u00a00\u00b72 for each comparison). Therefore, we observed no evidence that bortezomib\u2013lenalidomide\u2010based front\u2010line therapy precipitates earlier\n                    <jats:styled-content style=\"fixed-case\">EMD<\/jats:styled-content>\n                    .\n                  <\/jats:p>","DOI":"10.1111\/bjh.13382","type":"journal-article","created":{"date-parts":[[2015,6,2]],"date-time":"2015-06-02T19:53:16Z","timestamp":1433274796000},"page":"843-850","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide\u2013bortezomib combinations"],"prefix":"10.1111","volume":"169","author":[{"given":"Cindy","family":"Varga","sequence":"first","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanling","family":"Xie","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Laubach","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Paba\u2010Prada","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Warren","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Maglio","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schlossman","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edie","family":"Weller","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Mitsiades","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90021-6"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12005"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.9290"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01087.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05493.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_8_9_1","first-page":"47","article-title":"Clinical outcome of extramedullary plasmacytoma","volume":"85","author":"Galieni P.","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1805"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01399.x"},{"key":"e_1_2_8_15_1","first-page":"802","article-title":"Review: extramedullary disease in multiple myeloma","volume":"7","author":"Madan S.","year":"2009","journal-title":"Clinical Advances in Hematology & Oncology: H&O"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.09.018"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094409"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1414-5"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.01.010"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.29"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065698"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-007-9108-4"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp329"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802657751"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13382","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T23:51:17Z","timestamp":1696204277000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/bjh.13382"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13382","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"2014-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}